Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sight Sciences, Inc.

4.23
+0.11002.67%
Volume:228.93K
Turnover:965.09K
Market Cap:221.51M
PE:-4.41
High:4.29
Open:4.15
Low:4.12
Close:4.12
52wk High:7.05
52wk Low:2.03
Shares:52.37M
Float Shares:28.82M
Volume Ratio:2.91
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9597
EPS(LYR):-1.0274
ROE:-57.10%
ROA:-22.40%
PB:3.16
PE(LYR):-4.12

Loading ...

Sight Sciences Is Maintained at Neutral by Citigroup

Dow Jones
·
Aug 22

Sight Sciences Raised to Buy From Hold by Lake Street

Dow Jones
·
Aug 09

Sight Sciences (SGHT) Receives a Hold from Morgan Stanley

TIPRANKS
·
Aug 08

Sight Sciences Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Sight Sciences raises FY25 revenue view to $72M-$76M from $70M-$75M

TIPRANKS
·
Aug 08

Sight Sciences reports Q2 EPS (23c), consensus (28c)

TIPRANKS
·
Aug 08

Sight Sciences Q2 revenue falls 8% but beats estimates

Reuters
·
Aug 08

Sight Sciences Q2 EPS $(0.23) Beats $(0.29) Estimate, Sales $19.564M Beat $18.183M Estimate

Benzinga
·
Aug 08

Sight Sciences Inc - Raises 2025 Revenue Guidance to $72-$76 Mln

THOMSON REUTERS
·
Aug 08

Sight Sciences : Exposed to Tariffs Imposed by U.S. on China Because Most Products Are Produced and Assembled in China

THOMSON REUTERS
·
Aug 08

Sight Sciences Inc: Reiterates Adjusted Operating Expenses Guidance for Full Year 2025

THOMSON REUTERS
·
Aug 08

Sight Sciences: Tariff Exposure Would Increase Cost of Surgical Glaucoma Segment's Goods by $1.0 Mln -$1.5 Mln for FY

THOMSON REUTERS
·
Aug 08

Sight Sciences Q2 EPS USD -0.23

THOMSON REUTERS
·
Aug 08

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

GlobeNewswire
·
Aug 08

Sight Sciences Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
Aug 06

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

GlobeNewswire
·
Jul 30

Sight Sciences (SGHT) Receives a Hold from Lake Street

TIPRANKS
·
Jul 29

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

GlobeNewswire
·
Jul 29

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

GlobeNewswire
·
Jul 25

Sight Sciences Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Jul 15